Xlife Sciences Aktie
22,40CHF | -2,00CHF | -8,20% |
WKN DE: A2PK6Z / ISIN: CH0461929603
Personal
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 0 | 0 | 0 | 0 | 0 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
Bilanz (in Mio. EUR) - Aktiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 5 | 2 | 1 | 18 | 14 |
Summe Anlagevermögen | 183 | 275 | 296 | 325 | 365 |
Summe Aktiva | 186 | 480 | 490 | 512 | 540 |
Bilanz (in Mio. EUR) - Passiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Gesamtverschuldung/ -verbindlichkeiten | 52 | 63 | 61 | 57 | 59 |
Summe Fremdkapital | 56 | 161 | 153 | 147 | 144 |
Summe Eigenkapital | 130 | 319 | 338 | 365 | 397 |
Summe Passiva | 186 | 480 | 490 | 512 | 540 |
Adresse
Talacker 35, 8001 Zurich | |
Telefon | +41 (44) 385-84-60 |
Internet | http://www.xlifesciences.ch |
Management
Alexander Zink
Head-Technology & Innovation |
Beat Kläui
Head-Accounting & Tax |
Carl von Halem
Chief Financial Officer |
Christian Faber
Head-Legal & Compliance |
David L. Deck
Non-Executive Chairman |
Dennis Finch
Manager-Communications & Investor Relations |
Désirée Dosch
Non-Executive Director |
Frank Ploger
Chief Scientific Officer |
Mark S. Müller
Non-Executive Director |
Norbert Windhab
Non-Executive Director |
Oliver R. Baumann
Chief Executive Officer & Director |
Simone Bonito
Head-Administration |